{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:27:41Z","timestamp":1785414461803,"version":"3.56.0"},"reference-count":41,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["BG16RFPR002-1.014-0007"],"award-info":[{"award-number":["BG16RFPR002-1.014-0007"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"award":["BG16RFPR002-1.014-0007"],"award-info":[{"award-number":["BG16RFPR002-1.014-0007"]}],"id":[{"id":"https:\/\/ror.org\/019w4f821","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Bladder cancer is a molecularly heterogeneous malignancy in which biomarker-driven therapies increasingly shape clinical management. Fibroblast growth factor receptor 3 (FGFR3) alterations and nectin-4 expression are key therapeutic targets, yet their integrated biological and clinical relevance remains unclear. A systematic search of PubMed, Scopus, and Cochrane Central was conducted from database inception to 22 February 2026 (PROSPERO: CRD420261309413). Studies reporting the prevalence of FGFR3 alterations and\/or nectin-4 expression in bladder cancer were included. Proportions were pooled using a random-effects model with restricted maximum likelihood and Freeman\u2013Tukey transformation. Heterogeneity was assessed with I2 and Cochran\u2019s Q. Fourteen studies (three randomized and 11 observational), including 3955 patients (mean age: 67.34 years), were analyzed. The pooled prevalence of FGFR3 alterations was 52% (95% CI: 23.33\u201380.12; I2 = 99%), while that of nectin-4 expression was 78% (95% CI: 64.23\u201389.81; I2 = 91%). FGFR3 prevalence varied significantly by disease stage, study design, and region, with higher rates in advanced\/metastatic disease and randomized trials (p &lt; 0.05). Nectin-4 expression was generally high across included studies, although interpretation was limited by the small number of studies and assay variability. Sensitivity analyses showed the stability of estimates; however, interpretation is limited by substantial heterogeneity. The observed prevalence estimates are strongly influenced by study design, biomarker selection, and assay variability, limiting their interpretation as true biological prevalence. These results should, therefore, be interpreted cautiously and viewed as descriptive rather than definitive estimates. Separate analyses of biomarker-enriched trials and unselected cohorts are necessary to obtain clinically meaningful estimates.<\/jats:p>","DOI":"10.3390\/ijms27115007","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:45:08Z","timestamp":1780404308000},"page":"5007","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["FGFR3 Alterations and Nectin-4 Expression as Therapeutic Biomarkers in Bladder Cancer: A Systematic Review and Single-Arm Meta-Analysis"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4805-9178","authenticated-orcid":false,"given":"Petar","family":"Antonov","sequence":"first","affiliation":[{"name":"Department of Urology and General Medicine, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2201-0448","authenticated-orcid":false,"given":"Gabriela","family":"Raycheva","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4601-370X","authenticated-orcid":false,"given":"Denis","family":"Eshrefov","sequence":"additional","affiliation":[{"name":"Department of Urology and General Medicine, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Belov","sequence":"additional","affiliation":[{"name":"Department of Urology and General Medicine, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petar","family":"Uchikov","sequence":"additional","affiliation":[{"name":"Department of Special Surgery, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8831-3957","authenticated-orcid":false,"given":"Atanas","family":"Ivanov","sequence":"additional","affiliation":[{"name":"Department of Urology and General Medicine, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6423-9665","authenticated-orcid":false,"given":"Veselin","family":"Popov","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7293-1304","authenticated-orcid":false,"given":"Matteo","family":"Pacini","sequence":"additional","affiliation":[{"name":"Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2252-4297","authenticated-orcid":false,"given":"Alessandro","family":"Zucchi","sequence":"additional","affiliation":[{"name":"Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5178-9510","authenticated-orcid":false,"given":"Andrea","family":"Nicolini","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9942-9357","authenticated-orcid":false,"given":"Plamen","family":"Penchev","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1038\/modpathol.2009.26","article-title":"Histological variants of urothelial carcinoma: Diagnostic, therapeutic and prognostic implications","volume":"22","author":"Amin","year":"2009","journal-title":"Mod. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.juro.2013.05.040","article-title":"The impact of histological reclassification during pathology re-review\u2014evidence of a Will Rogers effect in bladder cancer?","volume":"190","author":"Linder","year":"2013","journal-title":"J. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, singlearm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody\u2013drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody\u2013drug conjugate-based therapeutics: State of the science","volume":"111","author":"Birrer","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody\u2013drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.annonc.2023.10.794","article-title":"Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF\/FGFR genomic alterations: Final results from FIGHT-201","volume":"35","author":"Necchi","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s12094-021-02717-3","article-title":"Expressions of PD-L1 and Nectin-4 in urothelial cancer patients treated with pembrolizumab","volume":"24","author":"Ueki","year":"2022","journal-title":"Clin. Transl. Oncol."},{"key":"ref_12","unstructured":"Higgins, J., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M., and Welch, V. (2026, March 28). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (Updated August 2023). Cochrane. Available online: www.cochrane.org\/handbook."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014A web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Nakagawa, S., Noble, D.W.A., Senior, A.M., and Lagisz, M. (2017). Meta-evaluation of meta-analysis: Ten appraisal questions for biologists. BMC Biol., 15.","DOI":"10.1186\/s12915-017-0357-7"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1214\/aoms\/1177729756","article-title":"Transformations related to the angular and the square root","volume":"21","author":"Freeman","year":"1950","journal-title":"Ann. Math. Stat."},{"key":"ref_19","unstructured":"(2026, April 01). R Core Team R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. Available online: https:\/\/www.R-project.org\/."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.annonc.2023.09.3116","article-title":"Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer","volume":"35","author":"Catto","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.annonc.2023.10.003","article-title":"Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: Cohort 2 of the randomized phase III THOR trial","volume":"35","author":"Park","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Hsueh, F.J., Wang, C.C., Guo, J.C., Chueh, S.C., and Tsai, Y.C. (2025). Impact of Membranous Nectin-4 on Outcomes of Platinum-Based Chemotherapy in Metastatic Urothelial Carcinoma. Cancers, 17.","DOI":"10.3390\/cancers17030433"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"102465","DOI":"10.1016\/j.clgc.2025.102465","article-title":"Impact of FGFR3 Alterations on First-Line Platinum Based Chemotherapy in Patients with Metastatic or Locally Advanced Urothelial Carcinoma: The Retrospective IFUCA Study","volume":"24","author":"Reverdy","year":"2026","journal-title":"Clin. Genitourin. Cancer."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e2500257","DOI":"10.1200\/PO-25-00257","article-title":"Fibroblast Growth Factor Receptor 3 Alteration Status and Outcomes on Immune Checkpoint Inhibitors in Patients with Metastatic Urothelial Carcinoma","volume":"9","author":"Gupta","year":"2025","journal-title":"JCO Precis Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.eururo.2020.07.018","article-title":"Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma","volume":"78","author":"Teo","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s00280-025-04783-8","article-title":"Clinical relevance of Nectin-4 downregulation and biological changes caused by cytotoxic chemotherapy in bladder cancer","volume":"95","author":"Miyake","year":"2025","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/bju.16643","article-title":"Spatial distribution and subtype-specific expression patterns of Nectin-4 in muscle-invasive bladder cancer","volume":"136","author":"Olah","year":"2025","journal-title":"BJU Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41416-021-01488-6","article-title":"Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: A real world experience","volume":"125","author":"Rose","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1158\/1078-0432.CCR-23-1283","article-title":"Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience","volume":"29","author":"Guercio","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance","volume":"29","author":"Ralser","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_32","first-page":"102517","article-title":"Role of FGFR3 in bladder cancer: Treatment landscape and future challenges","volume":"114","author":"Ascione","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/cac2.12602","article-title":"FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies","volume":"44","author":"Noeraparast","year":"2024","journal-title":"Cancer Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/his.15130","article-title":"Associations of TACSTD2\/TROP2 and NECTIN-4\/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts","volume":"84","author":"Bahlinger","year":"2024","journal-title":"Histopathology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"B014","DOI":"10.1158\/1557-3265.BLADDER24-B014","article-title":"FGFR inhibition upregulates Nectin-4 expression in FGFR3 altered urothelial carcinoma","volume":"30","author":"Zhou","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer","volume":"42","author":"Tran","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.annonc.2025.06.002","article-title":"The next-generation of nectin-4 targeted therapies","volume":"36","author":"Pobel","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_40","first-page":"17","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: 2024 update","volume":"85","author":"Witjes","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"11275","DOI":"10.1038\/s41467-024-55331-6","article-title":"AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer","volume":"15","author":"Bannier","year":"2024","journal-title":"Nat. Commun."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/11\/5007\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:22:08Z","timestamp":1780460528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/11\/5007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ijms27115007"],"URL":"https:\/\/doi.org\/10.3390\/ijms27115007","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}